NFGH
TCRR

Nan Fung Group Holdings’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History

Nan Fung Group Holdings’s Portfolio TCRR Stock Details TCRR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-19,335
Closed -$56K – 43
2022
Q2 		$56K Hold
19,335
– – 0.04% 40
2022
Q1 		$53K Buy
+19,335
New +$60.8K 0.03% 45

Other funds holding TCRR

MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nan Fung Group Holdings's TCRR Position: Q3 2022 in Review

Nan Fung Group Holdings sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q3 2022, closing a stake of 19,335 shares — an estimated $56K sold.

Nan Fung Group Holdings first reported a position in TCRR in Q1 2022 and held it in 2 quarters. The position peaked at $56K in Q2 2022. 81 funds tracked by Wall St. Rank hold TCRR as of Q3 2022.

  • Nan Fung Group Holdings reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Nan Fung Group Holdings sold 19,335 TCR2 Therapeutics Inc. Common Stock shares in Q3 2022, an estimated $56K.
  • Nan Fung Group Holdings first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2022 and held it in 2 quarters.
  • Nan Fung Group Holdings's TCR2 Therapeutics Inc. Common Stock position peaked at $56K in Q2 2022.
  • 81 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q3 2022.

Based on Nan Fung Group Holdings's 13F filing for Q3 2022, filed 10 Nov 2022.